keyword
MENU ▼
Read by QxMD icon Read
search

Glargine

keyword
https://www.readbyqxmd.com/read/29143919/iglarlixi-reduces-glycated-hemoglobin-to-a-greater-extent-than-basal-insulin-regardless-of-levels-at-screening-post-hoc-analysis-of-lixilan-l
#1
Elisabeth Niemoeller, Elisabeth Souhami, Yujun Wu, Klaus H Jensen
INTRODUCTION: The treatment of patients with type 2 diabetes uncontrolled on basal insulin and oral glucose-lowering drugs was investigated previously in the LixiLan-L trial. In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks. In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA1c) levels from screening, both for the overall category and for screening HbA1c subcategories...
November 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29141162/safety-of-degludec-versus-glargine-in-type-2-diabetes
#2
LETTER
(no author information available yet)
New England Journal of Medicine, Volume 377, Issue 20, Page 1994-1996, November 2017.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29140602/the-cardiovascular-safety-of-long-acting-insulin-analogues-in-type-2-diabetes-is-there-a-better-basal-insulin
#3
Chia-Hsuin Chang, Lee-Ming Chuang
In 2008, the U.S. Food and Drug Administration requested that all new type 2 anti-diabetic drugs, including long-acting insulin analogues, need to be rigorously examined to preclude undesirable cardiovascular risks. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the first trial to provide conclusive evidence of the cardiovascular safety of insulin glargine. A total of 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes were randomized to receive insulin glargine or standard care...
November 15, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29129018/a-32-week-randomized-comparison-of-stepwise-insulin-intensification-of-biphasic-insulin-aspart-biasp%C3%A2-30-versus-basal-bolus-therapy-in-insulin-na%C3%A3-ve-patients-with-type-2-diabetes
#4
Sultan Linjawi, Byung-Wan Lee, Ömür Tabak, Susanna Lövdahl, Shanti Werther, Salahedeen Abusnana
INTRODUCTION: This 32-week, open-label, randomized, parallel-group, multinational trial aimed to compare the efficacy and safety of stepwise insulin intensification of biphasic insulin aspart 30 (BIAsp 30) relative to stepwise intensification of a basal-bolus regimen in insulin-naïve adults with type 2 diabetes (T2D) who continued pretrial treatment with metformin and sulfonylurea. METHODS: Adults with T2D were randomized into one of two treatment arms for 32 weeks: (1) BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID); (2) insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID...
November 11, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29114384/treatment-with-insulin-analogs-and-prevalence-of-cardiovascular-complications-in-patients-with-type-1-diabetes
#5
Christoph Hasslacher, Justo Lorenzo Bermejo
Background: A lower incidence of cardiovascular events has been reported in type 2 diabetes patients treated with insulin analogs (IAs). Corresponding data on people affected by type 1 diabetes are not available yet. Methodology: We investigated demographic and clinical data from 509 type 1 diabetics, who were treated in an outpatient clinic from 2006 to 2012. Multiple logistic regression was used to investigate the relationship between the type of insulin treatment and the prevalence of cardiovascular (CV) complications, that is, presence of coronary heart, cerebrovascular and peripheral arterial diseases, adjusting for potential confounders...
November 2017: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29110972/patient-reported-outcomes-in-patients-with-type-2-diabetes-treated-with-dulaglutide-added-to-titrated-insulin-glargine-award-9
#6
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado, Kristina S Boye
PURPOSE: This 28-week, randomized, double-blind study compared a once-weekly injection of dulaglutide 1.5 mg to placebo, both added to titrated once-daily insulin glargine (with or without metformin), in patients with type 2 diabetes mellitus and inadequate glycemia control (control defined as hemoglobin A1c, ≥7% and ≤10.5%). Patient-reported outcomes were assessed as an exploratory objective to further understand patients' physical, psychological, and social aspects of well-being and injection-device experience...
October 27, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29106816/insulin-glargine-300-u-ml-is-associated-with-less-weight-gain-while-maintaining-glycemic-control-and-low-risk-of-hypoglycemia-compared-with-insulin-glargine-100-u-ml-in-an-aging-population-with-type-2-diabetes
#7
Medha N Munshi, Jasvinder Gill, Jason Chao, Elena V Nikonova, Meenakshi Patel
OBJECTIVE: Assess efficacy, hypoglycemia and weight gain in patients with type 2 diabetes (T2D) treated with insulin glargine 300 U/mL (Gla-300) or 100 U/mL (Gla-100) across different age groups. METHODS: Pooled data were generated for patients randomized to Gla-300 or Gla-100 in the EDITION 2 (NCT01499095) and 3 (NCT01676220) studies. In four age groups (<55, ≥55 to <60, ≥60 to <65, ≥65 years), glycated hemoglobin A1C (A1C), percentage of patients reaching A1C <7...
November 6, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29094298/optimizing-glycemic-control-through-titration-of-insulin-glargine-100-u-ml-a-review-of-current-and-future-approaches-with-a-focus-on-asian-populations
#8
REVIEW
Chaicharn Deerochanawong, Shailendra Bajpai, I Made Pande Dwipayana, Zanariah Hussein, Maria Aileen Mabunay, Reynaldo Rosales, Shih-Tzer Tsai, Man Wo Tsang
Various data have demonstrated inadequate glycemic control amongst Asians with type 2 diabetes mellitus (T2DM), possibly on account of suboptimal titration of basal insulin-an issue which needs to be further examined. Here we review the available global and Asia-specific data on titration of basal insulin, with a focus on the use of insulin glargine 100 U/mL (Gla-100). We also discuss clinical evidence on the efficacy and safety of titrating Gla-100, different approaches to titration, including some of the latest technological advancements, and guidance on the titration of basal insulin from international and local Asian guidelines...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29090977/observational-registry-of-basal-insulin-treatment-in-patients-with-type-2-diabetes-in-china-safety-and-hypoglycemia-predictors
#9
Tingting Zhang, Linong Ji, Yan Gao, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Fang Zhao, Heng Zhang, Xiaohui Guo
BACKGROUND: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal insulin (BI) in real-world settings in China. METHODS: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months...
November 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/29090600/comparison-between-insulin-degludec-liraglutide-treatment-and-insulin-glargine-lixisenatide-treatment-in-type-2-diabetes-a-systematic-review-and-meta-analysis
#10
Xiaoling Cai, Xueying Gao, Wenjia Yang, Linong Ji
AIM: To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS: The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included. RESULTS: Eight trials were included. The absolute HbA1c change relative to baseline after IGlarLixi treatment was -1...
November 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29089189/metformin-intoxication-vasopressin-s-key-role-in-the-management-of-severe-lactic-acidosis
#11
Francesca Galiero, Giovanni Consani, Gianni Biancofiore, Stefano Ruschi, Francesco Forfori
Vasopressin is a potent vasopressor used for improving organ perfusion during cardiac arrest, septic and catecholamine-resistant shock; with reference to this, it is useful for the treatment of vasoplegic shock because, restoring organ perfusion pressure by contraction of vascular smooth muscle through a non-catecholamine receptor pathway, it can be employed when catecholamines are ineffective. A 49-yr-old woman was admitted to the Emergency Department after having intentionally taken 95.2g of metformin, 1...
October 28, 2017: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29083520/all-cause-and-diabetes-related-healthcare-costs-among-u-s-adults-with-type-2-diabetes-initiating-exenatide-once-weekly-or-insulin-glargine
#12
Eric Wittbrodt, Amanda M Kong, Laura Moore-Schiltz, Paul Juneau
AIMS: To compare healthcare utilization and costs between patients with type 2 diabetes (T2D) treated with exenatide (Bydureon®) once weekly (EQW) and patients treated with insulin glargine (IG). MATERIALS AND METHODS: Using the MarketScan® Commercial and Medicare Supplemental databases, we conducted a retrospective cohort study of adult US patients with ≥1 claim for T2D initiating EQW or IG from 2/1/2012 to 6/30/2014 (first claim=index date). All-cause and diabetes-related utilization and costs were measured in the 12 months after index date...
October 30, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29080210/cost-effectiveness-of-exenatide-once-weekly-versus-insulin-glargine-and-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-greece
#13
Charalampos Tzanetakos, Alexandra Bargiota, Georgia Kourlaba, George Gourzoulidis, Nikos Maniadakis
OBJECTIVE: The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy in Greece. METHODS: The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime...
October 27, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29058131/insulin-and-its-cardiovascular-effects-what-is-the-current-evidence
#14
REVIEW
Sahana Pai Dongerkery, Pamela R Schroeder, Mansur E Shomali
PURPOSE OF REVIEW: In this article, we examine the nature of the complex relationship between insulin and cardiovascular disease. With metabolic abnormalities comes increased risk for cardiovascular complications. We discuss the key factors implicated in development and progression of cardiovascular disease, its relationship to insulin therapy, and what can be learned from large, recent cardiovascular outcome studies. RECENT FINDINGS: Preclinical studies suggest that insulin has positive effects of facilitating glucose entry into cells and maintaining euglycemia and negative effects of favoring obesity and atherogenesis under certain conditions...
October 23, 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/29044860/effects-of-exenatide-twice-daily-exenatide-once-weekly-or-insulin-in-patients-with-type-2-diabetes-and-baseline-hba1c-%C3%A2-10-0-two-pooled-analyses-including-20-randomised-controlled-trials
#15
Robert S Busch, James Ruggles, Jenny Han, Elise Hardy
AIMS: Patients with advanced type 2 diabetes (T2D) and high glycated haemoglobin (HbA1c) values can be difficult to treat because of their severe metabolic disease. This pooled analysis examined the treatment effects of exenatide twice daily (BID), exenatide once weekly (QW) and insulin in patients with high baseline HbA1c (≥10.0%). METHODS: This post hoc analysis used pooled data from 12 and 8 randomised controlled trials of exenatide BID and exenatide QW, respectively...
October 17, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29034415/a-diabetic-ketoacidosis-in-a-context-of-hyperglycemia-addiction
#16
Guillaume Rousseau, Cristian Palmiere, Vincent Dupont, Marion Verschoore, Caroline Savary, Nathalie Jousset, Clotilde Rougé-Maillart
We herein present a case of a 20-year-old woman who suffered from type I diabetes mellitus and died from a diabetic ketoacidosis in a context of addiction to hyperglycemia. Diabetic ketoacidosis is a lethal complication of insulin-dependent diabetes mellitus, which can result from insulin therapy stoppage. This can occur voluntarily with suicidal intent or involuntarily due to treatment inaccessibility, forgotten injections, or material deficiency. A new possibility is investigated in our case study: hyperglycemia addiction...
October 15, 2017: International Journal of Legal Medicine
https://www.readbyqxmd.com/read/29029025/insulin-deficient-mouse-%C3%AE-cells-do-not-fully-mature-but-can-be-remedied-through-insulin-replacement-by-islet-transplantation
#17
Adam Ramzy, Majid Mojibian, Timothy J Kieffer
Insulin receptor insufficiency in β-cells leads to impaired insulin secretion and reduced β-cell hyperplasia in response to hyperglycemia. Selective insulin receptor deficiency in β-cells in later embryological development may lead to compensatory β-cell hyperplasia. Though these findings suggest insulin signaling on the β-cell is important for β-cell function, they are confounded by loss of signaling by the IGFs through the insulin receptor. To determine if insulin itself is necessary for β-cell development and maturation, we performed a characterization of pancreatic islets in mice with deletions of both non-allelic insulin genes (Ins1-/-Ins2-/-)...
September 27, 2017: Endocrinology
https://www.readbyqxmd.com/read/29017173/insulin-regimens-to-treat-hyperglycemia-in-hospitalized-patients-on-nutritional-support-systematic-review-and-meta-analyses
#18
Marina Verçoza Viana, Luciana Verçoza Viana, Ana Laura Tavares, Mirela Jobim de Azevedo
BACKGROUND: The best insulin regimen to treat hyperglycemia in hospitalized patients on nutritional support (NS) is unclear. METHODS: We searched electronic databases to identify cohort studies or randomized clinical trials in order to evaluate the efficacy of different insulin regimens used to treat hyperglycemia in hospitalized patients on NS on diverse outcomes: mean blood glucose (MBG), hypoglycemia, length of stay in hospital, and mortality. RESULTS: Seventeen studies from a total of 5,030 were included...
October 6, 2017: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/28970434/comparison-of-insulin-detemir-and-insulin-glargine-for-hospitalized-patients-on-a-basal-bolus-protocol
#19
Sondra Davis, Chad Friece, Nicki Roderman, Darrell Newcomer, Evangelina Castaneda
BACKGROUND: The primary purpose of this study is to determine whether insulin detemir is equivalent to insulin glargine in controlling hyperglycemia for the adult hospitalized patient on a basal-bolus treatment regimen. METHODS: A retrospective study was conducted at two acute care hospitals within the same health system. Patients from both facilities who were initiated on a basal-bolus subcutaneous insulin regimen were included in the study. The basal-bolus regimen consisted of three components: basal, bolus, and corrective insulin with only the data from the first seven days analyzed...
April 23, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28960085/the-clinical-effectiveness-of-insulin-glargine-in-patients-with-type-i-diabetes-in-brazil-findings-and-implications
#20
Lays P Marra, Vânia E Araújo, Gerusa Cc Oliveira, Leonardo M Diniz, Augusto A Guerra Júnior, Francisco de Assis Acurcio, Brian Godman, Juliana Álvares
AIM: Published studies have challenged the cost-effectiveness of insulin glargine versus neutral protamine hagedorn (NPH) insulins in Brazil with limited evidence of increased effectiveness despite considerably higher acquisition costs. However, still a controversy. Consequently, there is a need to address this. MATERIALS & METHODS: Retrospective cohort study of Type I diabetes patients receiving insulin glargine in Brazil following NPH insulin who met the criteria...
September 29, 2017: Journal of Comparative Effectiveness Research
keyword
keyword
25751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"